Related Experiment Video
Updated: Feb 10, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials
Tomoya Yokota1, Johanna Bendell2, Patricia LoRusso3
1Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Background:
We examined the impact of race on the maximum tolerated doses (MTD) and final approved doses (FAD) of single-agent molecular-targeted agents (MTA) in North America/Europe (NA/EU) and Asia.
Methods:
We searched PubMed and regulatory databases to identify targeted drugs approved globally and compared their FAD and MTD in corresponding phase I/II studies conducted separately in NA/EU and Asia. To evaluate this further, we conducted parallel, prospective, first-in-human studies of DS-7423, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumours in the US and Japan. We pooled and compared the pharmacokinetics (PK), pharmacodynamics (PD), toxicity, and efficacy between these populations.
Results:
17 MTA were approved in NA/EU and Asia from 2001 to 2015. Recommended phase 2 doses (RP2D) were identical across races in 14 of 17 (80%) studies and differences were not clinically meaningful. FAD were identical across all regions. 42 and 27 patients from US and Japan, respectively, were enrolled in the phase I studies of DS-7423. Despite differences in race, body weight, and body mass index, the RP2D were 240 mg/day with no differences in toxicities, PK, PD, or efficacy.
Conclusions:
Conducting separate clinical trials of single-agent MTA in Caucasian and Asian populations may be redundant.
Related Concept Videos
Dose-Response Relationship: Selectivity and Specificity
RACE - Rapid Amplification of cDNA Ends
Trial and Error and Algorithm
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Impact of Groups on Groups

